Oslo, Norway, 16 February 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below).
Are you a startup or entrepreneur in Healthcare or Life-Sciences? If yes - keep reading!
Meltwater Newsfeed :
- PCI Biotech: Invitation to fourth quarter 2016 presentation February 20, 2017
- NASDAQ OMX GlobeNewswire - PCI Biotech: Invitation to fourth February 20, 2017
- MeldingsID: 420665 February 20, 2017
- Invitation to fourth quarter 2016 presentation February 20, 2017